Early Postprostatectomy RT Reduces Risk of Biochemical Failure

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 1
Volume 8
Issue 1

PHOENIX-A matched-pair analysis suggests that early postoperative adjuvant radiation therapy significantly re-duces the risk of biochemical failure in prostate cancer patients with capsular penetration after prostatectomy.

PHOENIX—A matched-pair analysis suggests that early postoperative adjuvant radiation therapy significantly re-duces the risk of biochemical failure in prostate cancer patients with capsular penetration after prostatectomy.

The Thomas Jefferson University researchers identified 149 patients at the Kimmel Cancer Center who had capsular penetration and absence of nodal metastasis after prostatectomy. “None of these patients had elevated postoperative PSA within 6 months of the time of radical prostatectomy. They received no prior hormonal therapy or chemotherapy,” Richard K. Valicenti, MD, said at the annual meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO).

From this group, the researchers matched 36 patients who received adjuvant radiation therapy and 36 patients who did not receive adjuvant therapy for preoperative PSA, Gleason score, surgical margin status, and seminal vesicle invasion. “These are prognostic factors highly predictive of biochemical failure and outcome,” Dr. Valicenti said.

With a median follow-up of 41 months (minimum, 2 years), the study showed 17 biochemical failures among the patients who did not receive adjuvant radiation therapy, compared with only four such failures in the adjuvant therapy group.

“There was 93% biochemical control in the patients who received adjuvant irradiation vs 66% in patients who were observed,” Dr. Valicenti said. “This represents an 83% reduction in biochemical failure among patients who had adjuvant treatment.”

He added that the study has shown no difference in clinical outcomes (local control, disease-specific survival, or overall survival). “I think the lack of a survival difference is due more to the absence of clinical events rather than their presence,” he said.

Related Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Related Content